News
The day at a glance · 2 min read
Mood · Mixed
+15
Sentiment, −100 to +100
J&J RYBREVANT Median OS
34.3 months
Amgen Market Cap Loss
$12B-5%
Novo Nordisk 2026 Decline
12%
Key driverJohnson & Johnson's positive lung cancer survival data offset by Novartis pelacarsen Phase 3 failure rippling through cardiovascular drug developers
Daily briefHealthcare· Money365.Market AI ·

J&J Cancer Data Shines as Novo Rebrands, Novartis Flop Ripples

Johnson & Johnson reports 34.3-month survival in lung cancer trial; Novo Nordisk shortens name amid two-year decline; Amgen sheds $12 billion on rival's failure.

Big Pharma & Biotech

Neutral
JNJAMGNLLYBMY
Johnson & Johnson ($JNJ) reported final overall survival results from its Phase 3 PAPILLON study evaluating first-line RYBREVANT (amivantamab) plus carboplatin-pemetrexed chemotherapy in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Patients treated with the combination achieved a median overall survival of 34.3 months, described as the longest reported to date in this patient population. The therapy uses a differentiated approach that dual targets EGFR and MET.
Novo Nordisk is shortening its name to 'Novo' as part of an effort to boost its appeal to consumers in the obesity drug market. The Danish drugmaker has fallen approximately 12% in 2026 after losing more than half its value in 2025, its worst year since 1984. The rebranding represents an attempt at revival amid a challenging competitive landscape.
Amgen ($AMGN) shed roughly $12 billion in market value after hours on September 4, 2026, with the stock declining by approximately 5% to $415. The decline was triggered by Novartis announcing that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. The market reaction occurred despite Amgen not owning pelacarsen, raising questions about the company's own Lp(a) development program.
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China, reflecting continued investment in Asian biotech innovation.
Eli Lilly ($LLY) may be impacted by the Novartis pelacarsen failure, though reports suggest the impact will be limited.
Bristol Myers Squibb ($BMY) offers a 4% dividend yield as management addresses key operational issues.

Health Insurance & Managed Care

Neutral

UNH Dividend Per Share

$2.32
UNH
UnitedHealth Group ($UNH) recently announced a total dividend of $2.32 per share, with the ex-dividend date set for September 14, 2026. The amount consists of $2.32 per share in cash dividends, payable on September 22, 2026. Shareholders must have owned the stock before the ex-dividend date to qualify for the payment. The company is recognized as one of five dividend stocks raising payouts fast enough to counter inflation pressures.

MedTech & Devices

Neutral
ABT
Abbott Laboratories ($ABT) and Medtronic are both identified as medical device dividend giants that have raised their dividends for nearly half a century. The comparison centers on retirement investors with limited capital choosing between the two companies, with the decision framing centered on investor timeline considerations. Both companies operate in the medical device sector with long track records of consistent dividend growth.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy